NeuroPace Profit Margin

The latest profit margin for NPCE is -19.34% as of June 2026. That compares with -5.93% in the prior-year period — down 226.3% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside NeuroPace's historical trend and sector peers before judging valuation or financial health.

Over the past year, NPCE's profit margin moved from -5.93% to -19.34% — a 226.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NeuroPace's valuation or profitability profile.

Against Healthcare companies, NPCE currently prints -19.34% for profit margin, while the sector average sits near 21.34%. That is roughly 190.6% below the sector mean. Large gaps often invite a closer look at NeuroPace's growth, margins, and balance sheet.

Profit Margin shows how effectively NeuroPace converts resources into returns. At -19.34%, NPCE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5.93% in the prior-year period — down 226.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NPCE's profit margin (-19.34%), review year-over-year change from -5.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.